Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Aerie Pharmaceuticals Inc (AERI)  
$15.25 0.00 (0.00%) as of 4:30 Fri 11/18


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 47,361,000
Market Cap: 722.26(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $15.25 - $15.25
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Major

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 333
  Page 2 of 14  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Larocca John General Counsel   •       –      –    2022-03-18 4 A $0.00 $0 D/D 19,015 54,356     -
   Mcgraw Benjamin F III Interim Executive Chair   •       •      –    2022-02-28 4 D $8.30 $85,689 D/D (10,324) 35,739     -
   Larocca John General Counsel   •       –      –    2022-02-19 4 D $6.00 $11,838 D/D (1,973) 35,341     -
   Mitro Thomas A President and COO   •       –      –    2022-02-08 4 D $7.33 $8,144 D/D (1,111) 81,418     -
   Kopczynski Casey C. Chief Scientific Officer   •       –      –    2022-02-08 4 D $7.33 $5,131 D/D (700) 261,229     -
   Mitro Thomas A President and COO   •       –      –    2022-02-07 4 D $7.24 $9,484 D/D (1,310) 82,529     -
   Larocca John General Counsel   •       –      –    2022-02-07 4 D $7.24 $5,560 D/D (768) 37,314     -
   Kopczynski Casey C. Chief Scientific Officer   •       –      –    2022-02-07 4 D $7.24 $5,075 D/D (701) 261,929     -
   Kopczynski Casey C. Chief Scientific Officer   •       –      –    2022-02-06 4 D $7.05 $6,176 D/D (876) 262,630     -
   Mitro Thomas A President and COO   •       –      –    2022-02-06 4 D $7.05 $10,117 D/D (1,435) 83,839     -
   Larocca John General Counsel   •       –      –    2022-02-06 4 D $7.05 $2,707 D/D (384) 38,082     -
   Kopczynski Casey C. Chief Scientific Officer   •       –      –    2022-02-04 4 D $7.05 $6,789 D/D (963) 263,506     -
   Mitro Thomas A President and COO   •       –      –    2022-02-04 4 D $7.05 $10,117 D/D (1,435) 85,274     -
   Hollander David Chief R&D Officer   •       –      –    2022-02-04 4 D $7.05 $6,535 D/D (927) 30,749     -
   Larocca John General Counsel   •       –      –    2022-02-04 4 D $7.05 $8,502 D/D (1,206) 38,466     -
   Mcginley Kathleen CHRO & VP, Corp Services   •       –      –    2022-01-30 4 D $6.92 $6,076 D/D (878) 23,993     -
   Kannan Raj Chief Executive Officer   •       •      –    2021-12-20 4 A $0.00 $0 D/D 215,783 215,783     -
   Hollander David Chief R&D Officer   •       –      –    2021-11-11 4 D $12.06 $26,074 D/D (2,162) 31,676     -
   Calabrese Jeffrey Vice President of FinanceOffic   •       –      –    2021-10-29 3 IO $0.00 $0 D/D 0 8,019 -22%     
   Mcginley Kathleen CHRO & VP, Corp ServicesOffice   •       –      –    2021-10-06 3 IO $0.00 $0 D/D 0 24,871 -41%     
   Mcgraw Benjamin F III Interim Executive Chair   •       •      –    2021-09-20 4 A $0.00 $0 D/D 34,513 46,063     -
   Larocca John General Counsel   •       –      –    2021-08-14 4 D $14.70 $11,246 D/D (765) 39,672     -
   Staten Christopher Interim CFO   •       –      –    2021-08-14 4 D $14.70 $12,892 D/D (877) 21,710     -
   Staten Christopher Interim CFOOfficer   •       –      –    2021-07-30 3 IO $0.00 $0 D/D 0 22,587 -39%     
   Du Toit Michael Director   –       •      –    2021-06-17 4 A $0.00 $0 D/D 1,750 9,850     -
  333 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 14
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us